The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Vivimed Labs to clarify issues with its financial results for the quarter ended 31-March-2025, filed under SEBI's Listing Obligations and Disclosure Requirements (Regulation 33). Two specific concerns were raised: the results were not submitted in the format prescribed by SEBI, and the XBRL filing contained discrepancies. The company has not yet responded, and its clarification is awaited. Until the exchange receives a satisfactory response, the filing remains under query. This is a compliance-related matter regarding the accuracy and presentation of quarterly financial disclosures.
This raises concerns about the quality and compliance of Vivimed Labs' financial reporting. Investors may view this as a red flag on governance and disclosure standards, potentially weighing negatively on the stock in the short term until the company clarifies and rectifies the issues.